Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
TEVA

Teva

$23.29

-0.45 (-1.90%)

07:01
07/16/18
07/16
07:01
07/16/18
07:01
Recommendations
Teva analyst commentary at Cantor Fitzgerald »

Teva price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

NBIX

Neurocrine

$102.95

0.17 (0.17%)

, TEVA

Teva

$23.29

-0.45 (-1.90%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Recommendations
Neurocrine, Teva analyst commentary at JPMorgan »

Neurocrine price target…

NBIX

Neurocrine

$102.95

0.17 (0.17%)

TEVA

Teva

$23.29

-0.45 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

  • 16

    Sep

Friday
TEVA

Teva

$23.29

-0.45 (-1.90%)

, NVS

Novartis

$78.78

-0.15 (-0.19%)

17:47
07/13/18
07/13
17:47
07/13/18
17:47
Hot Stocks
FDA announces voluntary recall of several medicines containing valsartan »

The U.S. Food and Drug…

TEVA

Teva

$23.29

-0.45 (-1.90%)

NVS

Novartis

$78.78

-0.15 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

VRX

Valeant

$23.55

-0.69 (-2.85%)

, TEVA

Teva

$23.30

-0.44 (-1.85%)

12:08
07/13/18
07/13
12:08
07/13/18
12:08
Recommendations
Valeant, Teva analyst commentary at Evercore ISI »

Evercore says FDA…

VRX

Valeant

$23.55

-0.69 (-2.85%)

TEVA

Teva

$23.30

-0.44 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 10

    Sep

  • 16

    Sep

Thursday
NVS

Novartis

$78.82

1.67 (2.16%)

, TEVA

Teva

$23.80

0.04 (0.17%)

10:22
07/12/18
07/12
10:22
07/12/18
10:22
Hot Stocks
Novartis prevails in Gilenya patent challenge brought by Teva and Apotex »

The U.S. Patent and…

NVS

Novartis

$78.82

1.67 (2.16%)

TEVA

Teva

$23.80

0.04 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

PRGO

Perrigo

$77.75

-0.06 (-0.08%)

, MYL

Mylan

$36.16

-0.52 (-1.42%)

05:01
07/12/18
07/12
05:01
07/12/18
05:01
Downgrade
Perrigo, Mylan, Teva rating change at Goldman Sachs »

Perrigo downgraded to…

PRGO

Perrigo

$77.75

-0.06 (-0.08%)

MYL

Mylan

$36.16

-0.52 (-1.42%)

TEVA

Teva

$23.76

-0.39 (-1.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

Over a week ago
TEVA

Teva

$24.14

-0.1 (-0.41%)

13:55
07/10/18
07/10
13:55
07/10/18
13:55
Options
Teva put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

QD

Qudian

$8.12

-0.38 (-4.47%)

12:15
07/10/18
07/10
12:15
07/10/18
12:15
Options
Qudian put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$24.10

-0.03 (-0.12%)

10:49
07/09/18
07/09
10:49
07/09/18
10:49
Hot Stocks
Teva launches generic version of Uceris in U.S. »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 16

    Sep

TEVA

Teva

$23.69

0.12 (0.51%)

07:38
06/27/18
06/27
07:38
06/27/18
07:38
Recommendations
Teva analyst commentary at Citi »

Teva added to CIti's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.